Short Interest in Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Decreases By 34.7%

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) was the recipient of a large drop in short interest during the month of August. As of August 14th, there was short interest totaling 145,548 shares, a drop of 34.7% from the July 30th total of 222,920 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average daily trading volume, of 69,205 shares, the days-to-cover ratio is currently 2.1 days.

Wall Street Analyst Weigh In

Separately, BTIG Research began coverage on Serina Therapeutics in a report on Wednesday, July 1st. They set a “buy” rating and a $8.00 price target for the company. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Serina Therapeutics presently has a consensus rating of “Buy” and an average target price of $8.00.

Serina Therapeutics Stock Performance

Serina Therapeutics stock traded down $0.04 during trading hours on Wednesday, hitting $2.46. The stock had a trading volume of 28,606 shares, compared to its average volume of 1,730,654. The company has a 50-day moving average of $2.27 and a two-hundred day moving average of $2.01. The company has a quick ratio of 6.65, a current ratio of 6.65 and a debt-to-equity ratio of 0.16. Serina Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $5.83. The company has a market cap of $62.61 million, a PE ratio of -1.30 and a beta of 1.17.

Serina Therapeutics (NYSEAMERICAN:SER) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) earnings per share (EPS) for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.